Combination study for mantle cell lymphoma after BTK inhibitor therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two targeted drugs for people with mantle cell lymphoma that has not responded to or has returned after treatment with a BTK inhibitor. The drugs aim to block cancer cell growth and survival pathways to potentially control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have mantle cell lymphoma that has been confirmed by a biopsy.
- Your lymphoma must have at least one measurable spot on imaging (like a scan).
- You must have already tried at least one cancer treatment that included a BTK inhibitor (like ibrutinib or acalabrutinib), and your disease either didn't respond, got worse, or you couldn't tolerate the drug.
- You should be generally able to do daily activities (ECOG score 0-2).
- Your liver, kidneys, and bone marrow must be working well enough (can include support like blood transfusions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination treatment for people with mantle cell lymphoma that has come back or not responded to a BTK inhibitor. It aims to see if this new approach can help control the cancer.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This trial is testing a combination of three drugs (polatuzumab vedotin, bendamustine, and rituximab) for people with mantle cell lymphoma that has progressed after a BTK inhibitor. The goal is to see if this combination can help control the lymphoma. You'll receive the treatment intravenously (by IV) over several cycles.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.